Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 20/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | DRD3 | P35462 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105011 | 0.92 | P2RY12 (0.79) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4097467 | 0.91 | P2RY12 (0.70) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4097854 | 0.89 | P2RY12 (1.00) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3928973 | 0.87 | P2RY12 (0.64) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4105316 | 0.85 | P2RY12 (0.81) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3934955 | 0.85 | P2RY12 (0.63) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3922518 | 0.85 | P2RY12 (0.65) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4098057 | 0.85 | P2RY12 (1.00) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4737004 | 0.84 | P2RY12 (0.75) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4104695 | 0.83 | P2RY12 (1.00) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | claimed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | claimed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 853/4885CYP3A4 801/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885CYP2C9 453/4885CYP3A4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.